We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.


Fidelta is the fee-for-service operation of the Galapagos Group.

Fidelta has the necessary set up and expertise for fully integrated drug discovery, backed up by a successful delivery track record. Our goal is to provide efficacious, safe and differentiated preclinical candidates. We place strong emphasis on translational science, focusing on disease relevant animal models and ex-vivo studies where appropriate from patient samples, with the discovery process driven by expert medicinal chemistry and ADME/PK.

Inflammation and infection are our core expertise, accompanied by experience in additional therapeutic areas. Macrocyclic chemistry is a particular forte of Fidelta.